Better glycaemic control and risk reduction of diabetic complications in type 2 diabetes: Comparison with the DCCT

Diabetes Research and Clinical Practice

Volumn 42, Issue 2, 1998, Pages 77-83

  Molyneaux, L M ^a   Constantino, M I ^a   McGill, M ^a   Zilkens, R ^a   Yue, D K ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

DCCT; Microalbuminuria; Retinopathy; Risk reduction; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; DIABETIC RETINOPATHY; DISEASE CONTROL; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; HEALTH SERVICE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RISK ASSESSMENT;

ALBUMINURIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; RISK FACTORS;

EID: 0031740956     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00095-3     Document Type: Article

References (21)

1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl. J. Med. 329:1993;977-986.
2. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 44:1995;968-983.
3. The Diabetes Control and Complications Trial Research Group The absence of a glycaemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 45:1996;1289-1298.
4. Krolewski A.S., Laffel L.M.D., Krolewski M., Quinn M., Warram J.H. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. New Engl. J. Med. 332:1995;1251-1255.
5. Klein R., Klein B.E.K., Moss S.E., Davis M.D., DeMets D.L. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. J. Am. Med. Assoc. 260:1988;2864-2871.
6. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective study. Diab. Res. Clin. Pract. 28:1995;103-117.
7. Guillausseau P.J., Massin P., Charles M.A., Allaguy H., Guvenli Z., Virally M., Tielmans D., Assayag M., Warnet A., Lubetzki J. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study. Diabetic Med. 15:1998;151-155.
8. Emanuele N., Klein R., Abraira C., Colwell J., Comstock J., Henderson W.G., Levin S., Nuttall F., Sawin C., Silbert C., Lee H.S., Johnson-Nagel N. Evaluation of retinopathy in the VA Cooperative Study on glycaemic control and complications in type 11 diabetes (VA CSDM). A feasibility study. Diab. Care. 19:1996;1375-1381.
9. UK Prospective Diabetes Study Group Perspective in diabetes. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetes. 44:1995;1249-1258.
10. Nathan D.M. Inferences and implications. Do results from the Diabetes Control and Complications Trial Apply in NIDDM? Diab. Care. 18:1995;251-257.
11. McGill M., Molyneaux L.M., Yue D.K., Turtle J.R. A single visit diabetes complication assessment service: a complement to diabetes management at the primary care level. Diabetic Med. 10:1993;366-370.
12. Zelmanovitz T., Gross J.L., Oliveira J.R., Paggi A., Tatsch M., Azevedo M.J. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diab. Care. 20:1997;516-519.
13. Overland J., McGill M., Yue D.K. Ambulatory diabetes care: a diabetic centre based model. Pract. Diab. 14:1997;111-115.
14. World Health Organisation, Diabetes mellitus, report of a WHO Study Group. Tech. Rep. Ser. no. 727. World Health Org. Geneva, 1985, pp. 9-17.
15. Danne T., Weber B., Hartmann R., Enders I., Burger W., Hovener G. Long-term glycemic control has a nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Diab. Care. 17:1994;1390-1396.
16. Warram J.H., Manson J.E., Krolewski A.S. Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. New Engl. J. Med. 332:1995;1305-1306.
17. Janka H.U., Warram J.H., Rand L.I., Krolewski A.S. Risk factors for the progression of background in long-standing IDDM. Diabetes. 38:1989;460-464.
18. Smulders Y.M., Rakic M., Stehouwer C.D.A., Weijers R.N.M., Slaats E.H., Silverbusch J. Determinants of progression of microalbuminuria in patients with NIDDM. Diab. Care. 20:1997;999-1005.
19. Viberti G.C., Marshall S., Beech R., Brown V., Derben P., Higson N., Home P., Keen H., Plant M., Walls J. Report on Renal Disease, Diabetes. 13:1996;S6-S12.
20. Gaster B., Hirsch I.B. The effects of improved glycemic control on complications in type 2 diabetes. Arch. Intern. Med. 158:1998;134-140.
21. Ravid M., Brosh D., Ravid-Safran D., Levy Z., Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch. Intern. Med. 158:1998;998-1004.